Show simple item record

dc.contributor.authorLange, Sigrun
dc.contributor.authorKholia, Sharad
dc.contributor.authorKosgodage, Uchini S
dc.contributor.authorInal, Jameel
dc.contributor.editorNicholas, Anthony
dc.contributor.editorBhattacharya, Sanjoy
dc.contributor.editorThompson, Paul
dc.date.accessioned2018-01-24T13:51:57Z
dc.date.available2018-01-24T13:51:57Z
dc.date.issued2017
dc.identifier.citationLange , S , Kholia , S , Kosgodage , U S & Inal , J 2017 , Treatment of Prostate Cancer Using Deimination Antagonists and Microvesicle Technology. in A Nicholas , S Bhattacharya & P Thompson (eds) , Protein Deimination in Human Health and Disease . 2 edn , Springer, Cham , pp. 413-425 . https://doi.org/10.1007/978-3-319-58244-3
dc.identifier.isbn978-3-319-58243-6
dc.identifier.isbn978-3-319-58244-3
dc.identifier.otherPURE: 13070676
dc.identifier.otherPURE UUID: f5b3191a-c8f3-4c36-8d7b-bc10a49d5c41
dc.identifier.otherScopus: 85037841899
dc.identifier.urihttp://hdl.handle.net/2299/19614
dc.descriptionLange, Sigrun, et al, 'Treatment of prostrate cancer using deimination antagonists and microvesicle technology', in Anthony Nicholas, Sanjoy Bhattacharya, and Paul Thompson, eds., Protein Deimination in Human Health and Disease, 2nd. Edition, (Switzerland: Springer, 2017), ISBN: 978-3-319-58243-6, eBOOK ISBN: 978-3-319-58244-3, doi: 10.1007/978-3-319-58244-3.
dc.description.abstractCellular microvesicle (MV) release, which occurs in most eukaryotic cells, is also involved in cancer progression and has recently been associated with peptidylarginine deiminase (PAD)-driven protein deimination. Evidence points to the involvement of deiminated cytoskeletal proteins and changes in histone deimination in the mechanism of MV biogenesis. Elevated PAD expression observed in cancers may contribute to increased MV shedding from cancer cells and contribute to cancer progression. The use of pan-PAD inhibitor Cl-Amidine (Cl-Am) showed that, following the pharmacological inhibition of PAD-mediated deimination, cellular MV release was significantly reduced, rendering prostate cancer cells significantly more susceptible to chemotherapeutic drugs. Combined Cl-Am and methotrexate (MTX) treatment of prostate cancer cells increased the cytotoxic effect of MTX. Refined PAD inhibitors that selectively manipulate MV biogenesis may form part of novel combination therapies in cancer treatment.en
dc.format.extent12
dc.language.isoeng
dc.publisherSpringer, Cham
dc.relation.ispartofProtein Deimination in Human Health and Disease
dc.titleTreatment of Prostate Cancer Using Deimination Antagonists and Microvesicle Technology.en
dc.contributor.institutionSchool of Life and Medical Sciences
dc.contributor.institutionUniversity of Hertfordshire
dc.contributor.institutionBiosciences Research Group
dc.relation.schoolSchool of Life and Medical Sciences
rioxxterms.versionVoR
rioxxterms.versionofrecordhttps://doi.org/10.1007/978-3-319-58244-3
rioxxterms.typeOther
herts.preservation.rarelyaccessedtrue
herts.rights.accesstypeclosedAccess


Files in this item

FilesSizeFormatView

There are no files associated with this item.

This item appears in the following Collection(s)

Show simple item record